恒瑞医药(600276.SH)：注射用瑞康曲妥珠单抗获得药物临床试验批准通知书

Core Viewpoint - The company has received approval for clinical trials of its injectable drug, Rukangquzhu Single Antibody, which is aimed at treating advanced non-small cell lung cancer (NSCLC) patients with HER2 mutations [1] Group 1: Company Developments - The subsidiary, Suzhou Shengdiya Biopharmaceutical Co., Ltd., has been granted a clinical trial approval notice by the National Medical Products Administration [1] - The injectable Rukangquzhu Single Antibody is expected to be launched in China by May 2025 [1] - The drug is indicated for adult patients with unresectable locally advanced or metastatic NSCLC who have previously received at least one systemic therapy [1]